Abstract Low-intensity extracorporeal shockwave therapy (LI-ESWT) offers a biologically restorative approach to vasculogenic erectile dysfunction (ED) by improving penile perfusion and endothelial function rather than simply facilitating an erection. Evidence from randomized and sham-controlled trials demonstrates a consistent benefit in mild to moderate vasculogenic disease; however, variability in dosing and sham design continues to limit the certainty of guidelines. This review proposes a pragmatic, clinic-ready framework centered on two pillars. First, a phenotype-driven responder model prioritizing men with vasculogenic ED, preserved nocturnal tumescence, and controlled cardiometabolic risk factors, while setting realistic expectations for those with diabetes, fibrosis, or neurogenic etiologies. Second, a dose-transparent protocol standardizing the full treatment equation, including energy flux density, pulses per session, treatment fields, number of sessions, and spacing, to improve reproducibility and outcome interpretation. The review further integrates LI-ESWT into a broader treatment continuum that includes optimization of cardiovascular and hormonal factors, first-line phosphodiesterase-5 inhibitor (PDE5i) therapy, and surgical options when appropriate. LI-ESWT is positioned as a disease-modifying adjunct that can enhance PDE5i responsiveness or defer prosthesis consideration in well-selected vasculogenic phenotypes. Safety data remain favorable, with adverse events typically mild and transient. Clear definitions of clinical success, objective reassessment at three to six months and one to two years, and transparent dose reporting support shared decision-making and long-term management planning.
Julian et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: